{"public_id":"cl_0814d4c3ac9a84a6161e01b5a311fde3","status":"active","superseded_by_public_id":null,"corpus_id":205906485,"text":"Treatment benefits were greater in participants with higher baseline disease activity and fibrosis stage.","confidence":0.88,"paper":{"corpus_id":205906485,"title":"A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","url":"https://sah.borca.ai/papers/205906485"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.88,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_36210605ade2af18157939082e218a06","name":"cenicriviroc","description":"A dual antagonist of C-C chemokine receptor types 2 and 5 evaluated as a treatment for nonalcoholic steatohepatitis with fibrosis.","types":["drug","therapeutic agent"],"url":"https://sah.borca.ai/concepts/co_36210605ade2af18157939082e218a06"},{"public_id":"co_77e0ee2ff01280ffa1c6a47c59f94977","name":"higher disease activity","description":"Greater baseline severity of nonalcoholic steatohepatitis as reflected by higher disease activity scores.","types":["baseline characteristic"],"url":"https://sah.borca.ai/concepts/co_77e0ee2ff01280ffa1c6a47c59f94977"},{"public_id":"co_7a7d15bb1411c9b23034523666e5c0d4","name":"fibrosis stage","description":"The baseline stage of liver fibrosis used to stratify disease severity.","types":["baseline characteristic","measurement"],"url":"https://sah.borca.ai/concepts/co_7a7d15bb1411c9b23034523666e5c0d4"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_0814d4c3ac9a84a6161e01b5a311fde3"}